2022-06-01
Cost-effectiveness of first-line nivolumab plus ipilimumab combined with two cycles of platinum- doublet chemotherapy compared to four cycles of platinum-doublet chemotherapy in patients with advanced non-small-cell lung cancer in a Dutch healthcare system
Publication
Publication
Additional Metadata | |
---|---|
Heine, R.J.S.D. | |
hdl.handle.net/2105/61898 | |
Business Economics | |
Organisation | Erasmus School of Economics |
Jong, A.F. de. (2022, June). Cost-effectiveness of first-line nivolumab plus ipilimumab combined with two cycles of platinum- doublet chemotherapy compared to four cycles of platinum-doublet chemotherapy in patients with advanced non-small-cell lung cancer in a Dutch healthcare system. Business Economics. Retrieved from http://hdl.handle.net/2105/61898
|